Target family: Calcium- and sodium-activated potassium channels (K<sub>Ca</sub>, K<sub>Na</sub>) (type: vgic)
Target: K<sub>Ca</sub>2.1

Ligand: UCL1848 (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines.
Published in: Br J Pharmacol

Ligand: UCL1684 (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: UCL1684 (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: tubocurarine (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1945)
Primary target: no
Median affinity:  pIC50
Reference (Journal): The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines.
Published in: Br J Pharmacol

Ligand: tubocurarine (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1945)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: tubocurarine (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1945)
Primary target: no
Median affinity:  pIC50
Reference (Journal): Small-conductance, calcium-activated potassium channels from mammalian brain.
Published in: Science

Ligand: tetraethylammonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2.700000047683716 pIC50
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: tamapin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons.
Published in: J Biol Chem

Ligand: SKA-31 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.539999961853027 pEC50
Reference (Journal): Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Published in: Mol Pharmacol

Ligand: SKA-20 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.369999885559082 pEC50
Reference (Journal): Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Published in: Mol Pharmacol

Ligand: riluzole (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995), EMA (1996)
Primary target: no
Median affinity: 4.679999828338623 pEC50
Reference (Journal): Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Published in: Mol Pharmacol

Ligand: NS8593 (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons.
Published in: Mol Pharmacol

Ligand: NS309 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime).
Published in: Biochim Biophys Acta

Ligand: NS309 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: leiurotoxin I (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
Published in: J Biol Chem

Ligand: leiurotoxin I (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: Lei-Dab7 (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.21999979019165 pIC50
Reference (Journal): Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2.
Published in: J Biol Chem

Ligand: GW542573X (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.090000152587891 pEC50
Reference (Journal): Selective activation of the SK1 subtype of human small-conductance Ca2+-activated K+ channels by 4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 293 in the S5 segment.
Published in: Mol Pharmacol

Ligand: EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small conductance calcium-activated potassium channels: from structure to function.
Published in: Prog Neurobiol

Ligand: EBIO (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Control of electrical activity in central neurons by modulating the gating of small conductance Ca2+-activated K+ channels.
Published in: J Biol Chem

Ligand: dequalinium (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines.
Published in: Br J Pharmacol

Ligand: dequalinium (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: CM-TPMF (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.619999885559082 pEC50
Reference (Journal): Evidence for a common pharmacological interaction site on K(Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype.
Published in: Mol Pharmacol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Small-conductance, calcium-activated potassium channels from mammalian brain.
Published in: Science

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
Published in: Nature

Ligand: B-TPMF (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.510000228881836 pEC50
Reference (Journal): Evidence for a common pharmacological interaction site on K(Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype.
Published in: Mol Pharmacol

Ligand: bicuculline (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.800000190734863 pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines.
Published in: Br J Pharmacol

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Matching molecules to function: neuronal Ca2+-activated K+ channels and afterhyperpolarizations.
Published in: Toxicon